[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619111":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":102,"collaborators":7,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":106,"sex":111,"minAge":112,"maxAge":7,"enrollmentInfo":113,"targetDuration":7,"studyType":116,"phases":7,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":125,"whyStopped":7,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"Association for Innovation and Biomedical Research on Light and Image","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Aflibercept 8mg","Patients will be treated with Aflibercept 8 mg, according to the standard clinical practice, in a treat and extent regimen with the inclusion of a home monitoring application.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Joana F Tavares, PhD","CONTACT","+351 239 480137","home@aibili.pt",[20,34,42,53,64,72,83,94],{"facility":21,"status":7,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Espaço Médico de Coimbra, Lda.","Coimbra","Portugal","PT",{"type":26,"coordinates":27},"Point",[28,29],-8.41996,40.20686,{"lat":29,"lon":28},[32],{"name":33,"role":16,"phone":7,"phoneExt":7,"email":7},"João Figueira",{"facility":35,"status":7,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":36,"geoPoint":38,"contacts":39},"Unidade Local de Saúde de Coimbra, E.P.E.",{"type":26,"coordinates":37},[28,29],{"lat":29,"lon":28},[40],{"name":41,"role":16,"phone":7,"phoneExt":7,"email":7},"Cláudia Farinha",{"facility":43,"status":7,"city":44,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Unidade Local de Saúde de Leiria, E.P.E.","Leiria",{"type":26,"coordinates":46},[47,48],-8.80705,39.74362,{"lat":48,"lon":47},[51],{"name":52,"role":16,"phone":7,"phoneExt":7,"email":7},"Nuno Oliveira",{"facility":54,"status":7,"city":55,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Instituto Português de Microcirurgia Ocular, Lda.","Lisbon",{"type":26,"coordinates":57},[58,59],-9.1498,38.72509,{"lat":59,"lon":58},[62],{"name":63,"role":16,"phone":7,"phoneExt":7,"email":7},"José Roque",{"facility":65,"status":7,"city":55,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Unidade Local de Saúde de Lisboa Ocidental - Hospital de Egas Moniz",{"type":26,"coordinates":67},[58,59],{"lat":59,"lon":58},[70],{"name":71,"role":16,"phone":7,"phoneExt":7,"email":7},"Maria Picoto",{"facility":73,"status":7,"city":74,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Unidade Local de Saúde Loures-Odivelas","Loures",{"type":26,"coordinates":76},[77,78],-9.16845,38.83091,{"lat":78,"lon":77},[81],{"name":82,"role":16,"phone":7,"phoneExt":7,"email":7},"Belmira Beltrán",{"facility":84,"status":7,"city":85,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Unidade Local de Saúde de Santo António, E.P.E.","Porto",{"type":26,"coordinates":87},[88,89],-8.61097,41.1485,{"lat":89,"lon":88},[92],{"name":93,"role":16,"phone":7,"phoneExt":7,"email":7},"Miguel Lume",{"facility":95,"status":7,"city":85,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":96,"geoPoint":98,"contacts":99},"Unidade Local de Saúde de São João, E.P.E.",{"type":26,"coordinates":97},[88,89],{"lat":89,"lon":88},[100],{"name":101,"role":16,"phone":7,"phoneExt":7,"email":7},"Ângela Carneiro",{"type":103,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619111","home-monitoring-in-eamd-treatment-100619111",false,"NCT07340372","Home Monitoring in eAMD Treatment","HOME","Inclusion Criteria:\n\n* Adults (≥ 55 years old) with exudative AMD in the study eye.\n* Treatment-naïve patients or patients who have started treatment with IVT anti-VEGF (aflibercept 2 mg, aflibercept 8 mg, faricimab, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) up to 48 weeks before inclusion.\n* BCVA early treatment diabetic retinopathy study (ETDRS) letter score of 85 to 34 (approximate Snellen equivalent of 20\u002F20 to 20\u002F200) in the study eye with decreased vision determined to be primarily the result of eAMD.\n* Willing and able to comply with clinic visits and study-related procedures.\n* Provide informed consent signed by study participant or legally acceptable representative.\n* Own a working smartphone or tablet compatible with the OKKO Health application.\n* Be able to operate the application after training according to OKKO Health indications of use: be alert and mentally competent, has competent dexterity and has normal or corrected hearing to normal audio level.\n\nExclusion Criteria:\n\n* Evidence of macular edema due to any cause other than eAMD in either eye.\n* Other ocular disease in the study eye that could prevent an accurate evaluation of treatment efficacy like, diabetic macular edema, posterior uveitis, corneal opacity, vein occlusion, macular dystrophy.\n* IVT anti-VEGF or steroid implants (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium, triamcinolone, dexamethasone, fluocinolone) for more than 1 year before inclusion.\n* Treatment with ocriplasmin (JETREA®) in the study eye at any time.","ALL","55 Years",{"count":114,"type":115},80,"ESTIMATED","OBSERVATIONAL","The goal of this observational clinical study is to collect more information about the efficacy of Aflibercept 8 mg injections in people with eAMD. The main questions it aims to answer are:\n\n* To reassure patients and doctors with longer intervals using home monitoring app;\n* To assess patient reported outcomes (PROMs) and Value-based Healthcare.\n\nParticipants already taking Aflibercept 8 mg as part of their regular medical care for eAMD will undergo regular ophthalmological examination and use a home monitoring app, in a one year and a two-year treatment period.",[119],"Exudative Age-Related Macular Degeneration",[121,119,122,123,124],"Aflibercept 8 mg","Patient reported outcomes","Value-based Healthcare","Home monitoring app","NOT_YET_RECRUITING","2026-05-05",{"date":128,"type":129},"2026-05-06","ACTUAL",{"date":131,"type":115},"2026-05",{"date":133,"type":115},"2027-12",{"name":5,"class":6},8]